9783330090712 - activity of the novel bcr kinase inhibitor iqs019 in b-nhl di roué, gael; esteve-arenys, anna (6 risultati)
- Brossura
Da: moluna, Greven, Germaniamoluna
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 31,27
EUR 48,99 spedizioneSpedito da Germania a U.S.A.Quantità: Più di 20 disponibili
Condizione: New.
- Brossura
Da: Revaluation Books, Exeter, Regno UnitoRevaluation Books
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 74,27
EUR 11,68 spedizioneSpedito da Regno Unito a U.S.A.Quantità: 1 disponibili
Paperback. Condizione: Brand New. 64 pages. 8.66x5.91x0.15 inches. In Stock.
- Brossura
Da: preigu, Osnabrück, Germaniapreigu
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 33,25
EUR 70,00 spedizioneSpedito da Germania a U.S.A.Quantità: 5 disponibili
Taschenbuch. Condizione: Neu. Activity of the Novel BCR Kinase Inhibitor IQS019 in B-NHL | Gael Roué (u. a.) | Taschenbuch | 64 S. | Englisch | 2017 | LAP LAMBERT Academic Publishing | EAN 9783330090712 | Verantwortliche Person für die EU: preigu GmbH & Co. KG, Lengericher Landstr. 19, 49078 Osnabrück, mail[at]preigu[dot]de | An…bieter: preigu.
- Brossura
- Print on Demand
Da: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, GermaniaBuchWeltWeit Ludwig Meier e.K.
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 35,90
EUR 23,00 spedizioneSpedito da Germania a U.S.A.Quantità: 2 disponibili
Taschenbuch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Chronic lymphocytic leukemia, mantle cell lymphoma, follicular lymphoma and diffuse large B cell lymphoma represent various subtypes of B-cell lymphoid neoplasms with essential differences in cell origin, disease progression, and r…esponse to therapy. B-cell receptor (BCR) signaling has recently emerged as a central oncogenic pathway in these models, promoting tumor growth and survival. Here, we describe a new BCR-related kinase inhibitor, IQS019, which interacts with and efficiently prevents the activating phosphorylation of three apical BCR kinases (Syk, Lyn and Btk) in these models. Inhibition of BCR signaling by IQS019 leads to reduced cell proliferation, blockade of cell chemotaxis, and increased caspase-dependent apoptosis. Additionaly, in two different xenotransplant mouse models, treatment with IQS019 results in a remarkable decrease in BCR kinase phosphorylation and mitotic index, reduced tumor burden and tumor cell infiltration into the spleen. Altogether, these results warrant further investigation and clinical development of this novel BCR kinase inhibitor in mature B lymphoid malignancies. 64 pp. Englisch.
- Brossura
- Print on Demand
Da: buchversandmimpf2000, Emtmannsberg, BAYE, Germaniabuchversandmimpf2000
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 35,90
EUR 60,00 spedizioneSpedito da Germania a U.S.A.Quantità: 1 disponibili
Taschenbuch. Condizione: Neu. This item is printed on demand - Print on Demand Titel. Neuware -Chronic lymphocytic leukemia, mantle cell lymphoma, follicular lymphoma and diffuse large B cell lymphoma represent various subtypes of B-cell lymphoid neoplasms with essential differences in cell origin, disease progression, and respo…nse to therapy. B-cell receptor (BCR) signaling has recently emerged as a central oncogenic pathway in these models, promoting tumor growth and survival. Here, we describe a new BCR-related kinase inhibitor, IQS019, which interacts with and efficiently prevents the activating phosphorylation of three apical BCR kinases (Syk, Lyn and Btk) in these models. Inhibition of BCR signaling by IQS019 leads to reduced cell proliferation, blockade of cell chemotaxis, and increased caspase-dependent apoptosis. Additionaly, in two different xenotransplant mouse models, treatment with IQS019 results in a remarkable decrease in BCR kinase phosphorylation and mitotic index, reduced tumor burden and tumor cell infiltration into the spleen. Altogether, these results warrant further investigation and clinical development of this novel BCR kinase inhibitor in mature B lymphoid malignancies.VDM Verlag, Dudweiler Landstraße 99, 66123 Saarbrücken 64 pp. Englisch.
- Brossura
- Print on Demand
Da: AHA-BUCH GmbH, Einbeck, GermaniaAHA-BUCH GmbH
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 37,20
EUR 60,57 spedizioneSpedito da Germania a U.S.A.Quantità: 1 disponibili
Taschenbuch. Condizione: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Chronic lymphocytic leukemia, mantle cell lymphoma, follicular lymphoma and diffuse large B cell lymphoma represent various subtypes of B-cell lymphoid neoplasms with essential differences in cell origin, disease progression, and respon…se to therapy. B-cell receptor (BCR) signaling has recently emerged as a central oncogenic pathway in these models, promoting tumor growth and survival. Here, we describe a new BCR-related kinase inhibitor, IQS019, which interacts with and efficiently prevents the activating phosphorylation of three apical BCR kinases (Syk, Lyn and Btk) in these models. Inhibition of BCR signaling by IQS019 leads to reduced cell proliferation, blockade of cell chemotaxis, and increased caspase-dependent apoptosis. Additionaly, in two different xenotransplant mouse models, treatment with IQS019 results in a remarkable decrease in BCR kinase phosphorylation and mitotic index, reduced tumor burden and tumor cell infiltration into the spleen. Altogether, these results warrant further investigation and clinical development of this novel BCR kinase inhibitor in mature B lymphoid malignancies.
